Changes in free and free-to-total prostate specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancer.
暂无分享,去创建一个
L. Dogliotti | D. Fontana | A. Berruti | A. Mosca | A. Angeli | G. Fasolis | R. Tarabuzzi | M. Torta | M. Mari
[1] L. Dogliotti,et al. Randomized Comparison of Goserelin Acetate versus Mitomycin C plus Goserelin Acetate in Previously Untreated Prostate Cancer Patients with Bone Metastases , 1998, Tumori.
[2] J. Moul,et al. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients , 1997, Cancer.
[3] E. Metter,et al. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. , 1997, Urology.
[4] S. Fosså,et al. Assessment of hormone refractory prostate cancer. , 1997, Urology.
[5] M. van Glabbeke,et al. Phase II studies on prostate cancer. , 1997, Urology.
[6] U. Stenman,et al. Prostate-specific antigen, clinical use and staging: an overview. , 1997, British journal of urology.
[7] R. Dreicer. Metastatic prostate cancer: assessment of response to systemic therapy. , 1997, Seminars in urologic oncology.
[8] T. M. Chu,et al. Prostate-specific antigen and early detection of prostate cancer. , 1997, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[9] R. Rubinov,et al. Serum free/total prostatic-specific antigen in prostate cancer patients treated with LH-RH agonists. , 1997, European urology.
[10] F. Koga,et al. [Studies on changes in the ratio of free to total PSA after endocrine treatment of prostate carcinoma]. , 1996, Hinyokika kiyo. Acta urologica Japonica.
[11] W. Catalona. Clinical utility of measurement free and total prostate‐specific antigen (PSA): A review , 1996, The Prostate. Supplement.
[12] M. Egorin,et al. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. , 1995, Journal of Clinical Oncology.
[13] W. Catalona,et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. , 1995, JAMA.
[14] M. Manyak,et al. Practice trends in the diagnosis and management of prostate cancer in the United States. , 1995, The Journal of urology.
[15] D. Osoba,et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] K. Ansong. Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. , 1994, Urology.
[17] H. Lilja,et al. Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium. , 1993, Urology.
[18] U. Stenman,et al. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. , 1993, Clinical chemistry.
[19] S. Rosso,et al. Cancer Incidence in Turin: The Effect of Migration , 1993, Tumori.
[20] O. Nilsson,et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. , 1993, The Journal of urology.
[21] M Mazumdar,et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Miller,et al. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. , 1992, The Journal of urology.
[23] J. Oesterling,et al. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.
[24] J. Oesterling,et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. , 1991, The Journal of urology.
[25] U. Stenman,et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.
[26] N. Geller,et al. Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] W. Whitmore. The natural history of prostatic cancer , 1973, Progress in clinical and biological research.
[28] Elisa T. Lee,et al. A computer program for comparing K samples with right-censored data. , 1972, Computer programs in biomedicine.
[29] N. Nie,et al. Statistical Package for the Social Sciences , 1970 .